92243-74-8 Usage
Uses
Used in Pharmaceutical Industry:
4-Ethoxycarbonylmethylphenylboronic acid is used as an intermediate in organic synthesis for the development of new pharmaceutical compounds. Its stable and low reactivity properties make it a valuable component in the synthesis of various drugs.
Used in Scientific Research:
4-Ethoxycarbonylmethylphenylboronic acid is employed as a research tool in the study of chemical reactions and mechanisms, particularly in the field of organic chemistry. Its unique structure allows researchers to investigate its reactivity and potential applications in the synthesis of complex molecules.
Used in Production Processes:
4-Ethoxycarbonylmethylphenylboronic acid is utilized in the production of certain specialty chemicals and materials, where its stability and low reactivity are essential for achieving the desired product characteristics. Its use in these processes is often subject to strict safety and handling protocols due to its hazardous nature.
Check Digit Verification of cas no
The CAS Registry Mumber 92243-74-8 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 9,2,2,4 and 3 respectively; the second part has 2 digits, 7 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 92243-74:
(7*9)+(6*2)+(5*2)+(4*4)+(3*3)+(2*7)+(1*4)=128
128 % 10 = 8
So 92243-74-8 is a valid CAS Registry Number.
92243-74-8Relevant academic research and scientific papers
LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONIST AND USES THEREOF
-
, (2012/01/06)
Described herein is the LPAl antagonist {4'-[3-methyl-4-((R)-l-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-biphenyl-4-yl}-acetic acid (Compound 1), including pharmaceutically acceptable salts thereof. Also described are methods of preparing the LPAl antago
ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS
-
Page/Page column 17-18, (2010/06/22)
Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating LPA-dependent or LPA-mediated conditions or diseases.
